AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $582 | +2.3% | 47,841 | +5.5% | 0.00% | 0.0% |
| Q2 2023 | $569 | +41.9% | 45,341 | +25.5% | 0.00% | +50.0% |
| Q1 2023 | $401 | -9.1% | 36,141 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $441 | -99.9% | 36,141 | +21.1% | 0.00% | +50.0% |
| Q3 2022 | $312,000 | -39.5% | 29,841 | -37.9% | 0.00% | -33.3% |
| Q2 2022 | $516,000 | +10.7% | 48,041 | -2.4% | 0.00% | 0.0% |
| Q1 2022 | $466,000 | -18.1% | 49,241 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $569,000 | +21.1% | 49,241 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $470,000 | -1.1% | 49,241 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $475,000 | -2.5% | 49,241 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $487,000 | -57.2% | 49,241 | 0.0% | 0.00% | -57.1% |
| Q4 2020 | $1,137,000 | +63.6% | 49,241 | 0.0% | 0.01% | +40.0% |
| Q3 2020 | $695,000 | -53.2% | 49,241 | -50.0% | 0.01% | -16.7% |
| Q2 2020 | $1,486,000 | – | 98,482 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |